Protocol Number: 03-C-0038
Patients with Hodgkin's disease, anaplastic large cell lymphoma, cutaneous T cell lymphoma, and adult T cell leukemia or lymphoma may be eligible for this study. Candidates must have signs of tumor growth or recurrence following standard treatment, and their tumor cells must have a protein called CD30. Patients with early-stage disease, smoldering adult T cell leukemia, or limited patches of skin involvement may not enroll. Candidates will be screened with a medical history, physical examination, blood and urine tests, electrocardiogram (ECG), and imaging studies, including chest X-ray and CT scans, and possible skin biopsy. Skin lesions will be photographed. (See below for information on biopsies.) Participants will receive four 30-minute infusions of HeFi-1 intravenously (through a vein) in 28-day treatment cycles. The infusions will be given on days 0 (first day of the cycle), 3, 6, and 9 of each cycle. The 2-day period between infusions may be extended if drug side effects occur. The first dose will be given in the hospital. Subsequent doses will be given on an outpatient basis if no significant side effects develop after the first infusion. The drug dose will be increased in successive groups of three patients each, for a total of five different doses. Each dose will be two times higher than the previous one, except for the last dose, which will be 50 percent higher than that for the preceding group. Patients may continue treatment as long as their tumor is not growing and they do not develop antibodies to HeFi-1 or serious treatment side effects. In addition to the drug treatment, patients will undergo the following tests and procedures: - Blood draws. Blood samples will be collected several times to determine the safety of the treatment. - Lymph node biopsies or aspirates. Up to three biopsies or aspirates will be taken during the first treatment cycle to examine the effect of HeFi-1 on tumor cells. - Bone marrow biopsy before, and possibly after, treatment. For this test, the area of the hip is anesthetized and a special needle is used to draw bone marrow from the hipbone. A biopsy takes a piece of tissue or tumor to examine it under the microscope. Biopsies may be done with a large needle, called a needle biopsy, with a small sharp cookie-cutter instrument, called a punch biopsy, or with a small knife, called an excisional biopsy. The procedure is similar for each of these. After the skin is cleaned thoroughly, a small amount of numbing medicine is given as a shot into the skin around the biopsy site. Then, if a needle biopsy is being done, a needle is put through the skin into the tumor to pull out a small piece of tumor in the length of the needle. If a punch biopsy is being done, a cookie cutter-like instrument is pushed into the numbed skin, and a small piece of tissue is removed. If an excisional biopsy is required, depending on the location to be biopsied, this may be done in the operating room or the clinic. The tissue is removed by cutting a small piece of tumor with a sharp knife or scalpel.
Search The Studies | Help | Questions |
Warren Grant Magnuson Clinical Center (CC) |
||